| 郑志君 王晓蕊 邱涛 孙毓川 李嘉.参附注射液对老年慢性心衰患者血清NT-proBNP、H-FABP及CRP 水平的影响[J].现代生物医学进展英文版,2016,16(16):3134-3137. |
| 参附注射液对老年慢性心衰患者血清NT-proBNP、H-FABP及CRP 水平的影响 |
| Effect of Shenfu Injection on the SerumCRP, H-FABP and NT-proBNPLevels of Elderly Patients with Chronic Heart Failure |
| |
| DOI： |
| 中文关键词: 参附注射液 慢性心衰 NT-proBNP H-FABP CRP |
| 英文关键词: Chronic heart failure Reference injection NT-proBNP H-FABP CRP |
| 基金项目:河北省科技攻关基金项目(324410084) |
|
| Hits: 861 |
| Download times: 0 |
| 中文摘要: |
| 目的：探讨参附注射液对老年慢性心衰患者脑钠肽(NT-proBNP)、心脏型脂肪酸结合蛋白(H-FABP)及C- 反应蛋白(CRP)的
影响。方法：收集我院收治的慢性心力衰竭患者70 例，随机分为对照组和实验组，每组各35 例，对照组患者均给予相应常规对症
治疗，实验组患者在对照组基础上给予参附注射液静脉滴注，治疗结束后观察并比较两组患者治疗前后血清NT-proBNP、
H-FABP 及CRP水平的变化以及治疗效果。结果：与治疗前相比，两组患者治疗后血清NT-proBNP、H-FABP及CRP 水平与治疗
前相比均降低(P<0.05)；实验组患者治疗后血清NT-proBNP、H-FABP及CRP 水平与对照组患者相比较低(P<0.05)。实验组临床总
有效率与对照组相比较高，但差异无统计学意义(P>0.05)。结论：参附注射液能够降低老年慢性心衰患者血清NT-proBNP、
H-FABP 及CRP水平，提高临床疗效。 |
| 英文摘要: |
| Objective:To investigate the effect of Shenfu injection on the serum NT-proBNP, H-FABP and CRP levels of elderly
patients with chronic heart failure.Methods:70 patients with chronic heart failure were selected and randomly divided into the control
group and experimental group, 35 cases in each group. The control group was treated by conventional symptomatic treatment and the
experimental group was treated on the base of the control group with Shen Fu injection. The changes of serum CRP, H-FABP and
NT-proBNP levels before and after treatment and clinical efficacy were compared between two groups.Results:Compared with before
treatment, the serum NT-proBNP, H-FABP and CRP levels of both groups were significantly lower after treatment (P<0.05). Compared
with the control group, the serum NT-proBNP, H-FABP and CRP levels of the experimental group were obviously lower than those of
the control group after treatment (P<0.05). The clinical total effective rate was higher in the experimental group tha that of the control
group, but no significant difference was found between two groups (P>0.05).Conclusion:Shenfu injection could significantly decrease
the serum H-FABP, NT-proBNP and CRP levels of elderly patients with chronic heart failure and significantly enhance the clinical
efficacy. |
|
View Full Text
View/Add Comment Download reader |
| Close |
